Key result
Advances in cryoablation and aggressive pharmacological strategies have significantly improved the prognosis of pediatric non-postoperative junctional ectopic tachycardia.
Why the study?
Junctional ectopic tachycardia is a rare pediatric arrhythmia linked to high morbidity and mortality without adequate therapy, prompting a review of its natural history and treatment advances.
This review highlights that the prognosis for pediatric non-postoperative junctional ectopic tachycardia has improved due to advances in cryoablation and aggressive pharmacotherapy.
May support cryoablation referral in refractory pediatric JET; leaves open need for prospective trials on timing and durability.
Junctional ectopic tachycardia (JET) is a rare supraventricular tachycardia more frequently seen in pediatric patients which is associated with high morbidity and mortality without an adequate treatment. Its treatment often requires multiple drugs for arrhythmia control and, in some cases, a cryoablation is indicated. Some patients may revert to sinus rhythm spontaneously after long periods on antiarrhythmic drug. Currently, the arrhythmia prognosis has improved significantly since cryoablation development and the implementation of a more aggressive pharmacological treatment strategy. The purpose of this review is to describe the natural history of idiopathic JET and treatment advances.
No takes yet. Share an insight, caveat, or question.
Maldonado et al. (2019) conducted a review in Pediatric non-postoperative junctional ectopic tachycardia. Pharmacological treatment and cryoablation was evaluated. Advances in cryoablation and aggressive pharmacological strategies have significantly improved the prognosis of pediatric non-postoperative junctional ectopic tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: